News

Hi-Tech’s ofloxacin otic solution is the generic equivalent of Daiichi’s Floxin otic solution, 0.3% indicated for the treatment of bacterial infections of the ear which in 2007, had

Because the initial design goals of the HDL mimetic peptide therapeutic program have now been met, the company will now move rapidly to validate other key cardio-protective characteristics

The designation allows the company to have seven year market exclusivity for milatuzumab in multiple myeloma upon final approval by the FDA. Other financial benefits and incentives include

The definitive agreement calls for closing of the acquisition by April 30, 2008, or sooner if the investment bankers working on the financial aspects of the transaction are

In addition, Symbicort has provided a similar bronchodilatory response to albuterol. Bronchodilatory response is defined as the mean time to achieve improvement in lung function. In both studies,

The private equity investment is being led by Forward Ventures, Jafco, and Novartis Venture Fund, with significant participation from Fidelity Biosciences and MedImmune Ventures. Additional investors include Athenian

The multi-center study observed the effect of Cinryze on the frequency of hereditary angioedema (HAE) attacks. The primary endpoint was met with a 52% reduction in the number

Based on the clinical trial data, the investigators concluded that Angiotech’s 5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC) met the primary endpoint of the study: non-inferior in its ability

Pursuant to the settlement agreement, the company has expressly denied engaging in any wrongful conduct. The settlement calls for payment by the company of $36.7 million, plus approximately